On September 20, 2024, Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health Inc (HIMS, Financial), executed a sale of 12,651 shares of the company at a price of $16.79 per share. This transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 211,000 shares of the company.
Hims & Hers Health Inc (HIMS, Financial) is a telehealth company that provides modern personalized health and wellness experiences to consumers. The company offers a broad range of prescription medications, over-the-counter treatments, and other healthcare products.
Over the past year, the insider has sold a total of 242,738 shares and has not purchased any shares. This recent transaction is part of a broader trend observed at Hims & Hers Health Inc, where there have been 81 insider sells and only 1 insider buy over the last year.
On the day of the transaction, shares of Hims & Hers Health Inc were trading at $16.79. This pricing gives the company a market cap of approximately $3.56 billion. The price-earnings ratio of the company stands at 205.50, which is significantly higher than the industry median of 17.77.
According to the GF Value, the intrinsic value estimate for Hims & Hers Health Inc is $15.64 per share, making the stock Fairly Valued with a price-to-GF-Value ratio of 1.07. The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This sale by the insider might be of interest to current and potential investors, as it provides insight into the insider's perspective on the stock's valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
